Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer

Prostate cancer is the second leading cause of cancer death in American men. Despite the common nature of this disease, there is a poor understanding of biomarkers that predict responsiveness to immunotherapeutic agents such as the programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Manogue, Charlotte, Cotogno, Patrick, Ledet, Elisa, Lewis, Brian, Wyatt, Alexander W., Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459247/
https://www.ncbi.nlm.nih.gov/pubmed/30541755
http://dx.doi.org/10.1634/theoncologist.2018-0546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459247/
https://www.ncbi.nlm.nih.gov/pubmed/30541755
http://dx.doi.org/10.1634/theoncologist.2018-0546

Ejemplares similares